- About Us
- Advertise
- Editorial Information
- Contact Us
- Do Not Sell My Personal Information
- Privacy Policy
- Terms and Conditions
© 2024 MJH Life Sciences™ and BioPharm International. All rights reserved.
Univercells Technologies
Articles
AAV Manufacturing: The benefits of growing serum-free, suspension HEK293 cells in the scale-X™ fixed-bed bioreactor
In this study, HEK293F cells grown in scale-X bioreactor produce >3x higher AAV-2 vector, with 25-52% lower cost than the reference process.
From Tech Transfer to Commercial Scale Viral Manufacturing in 8 months - a CDMO Case Study
Webinar Date/Time: Thu, Jun 1, 2023 11:00 AM EDT
Lentivirus production study in the scale-X™ fixed-bed bioreactor
This study aims to evaluate harvest strategies and metabolite-based cell density estimation methods for Lentivirus production with HEK293T cells.
AAV manufacturing: reaching high capacity with serum-free, scalable production
Webinar Date/Time: Tue, Apr 11, 2023 11:00 AM EDT
Simplifying Seed Train: A Benchtop System for Intensified Inoculation of Large-Scale Bioreactors
Webinar Date/Time: Tue, Jan 24, 2023 11:00 AM EST
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells (Nov 2022)
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.
How to Find Success with Lentiviral Production Using Fixed Bed Bioreactor Technology
Monday, October 17, 2022 at 11am EDT | 4pm BST | 5pm CEST Why would a CDMO to leverage fixed-bed bioreactor technology to develop and produce GMP lentiviral vectors? Join us for a discussion on increasing quality and decreasing time and cost to accelerate time to clinic and market for lentiviral products with technology.
Scalable rubella production in scale-X™ bioreactor with MRC-5 cells
This application note demonstrates the successful transfer, optimization and scale-up of the Rubella vaccine manufacturing process from static flasks to scale-X™ bioreactors.